Aurora Cannabis Expands German Operations with New Licenses

Ticker: ACB · Form: 6-K · Filed: 2024-07-25T00:00:00.000Z

Sentiment: bullish

Topics: regulatory-approval, international-expansion, medical-cannabis

TL;DR

Aurora just got the green light to grow and make medical weed in Germany. Big move for Europe.

AI Summary

Aurora Cannabis Inc. announced on July 25, 2024, that its German facility has received expanded cultivation and unique research licenses from the German Federal Institute for Drugs and Medical Devices (BfArM). This allows Aurora to cultivate cannabis for research purposes and to produce medical cannabis in Germany, marking a significant step for its European operations.

Why It Matters

These expanded licenses enable Aurora to directly cultivate and produce medical cannabis within Germany, potentially reducing costs and increasing supply chain control for the European market.

Risk Assessment

Risk Level: medium — While positive, the impact of these new licenses on Aurora's financial performance and market share in Germany is yet to be fully realized and depends on market adoption and regulatory execution.

Key Players & Entities

FAQ

What specific types of cannabis cultivation and research are permitted by the new German licenses?

The licenses permit the cultivation of cannabis for research purposes and the production of medical cannabis within Germany.

Which regulatory body issued the expanded licenses to Aurora's German facility?

The German Federal Institute for Drugs and Medical Devices (BfArM) issued the expanded cultivation and unique research licenses.

What is the significance of these licenses for Aurora's European strategy?

These licenses are significant as they allow Aurora to directly cultivate and produce medical cannabis in Germany, strengthening its European presence and supply chain.

When was this news release submitted to the SEC?

The news release, as part of the 6-K filing, was submitted on July 25, 2024.

What form type is this SEC filing?

This is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

From the Filing

0001279569-24-000916.txt : 20240725 0001279569-24-000916.hdr.sgml : 20240725 20240725101030 ACCESSION NUMBER: 0001279569-24-000916 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240725 FILED AS OF DATE: 20240725 DATE AS OF CHANGE: 20240725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 241140282 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated July 25, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: July 25, 2024 EX-99.1 2 ex991.htm NEWS RELEASE DATED JULY 25, 2024 Exhibit 99.1 Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility NASDAQ | TSX: ACB Company's Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research EDMONTON, AB, July 25, 2024 /CNW/ - Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). Aurora's license grants the company continued domestic cultivation, which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company's local EU GMP facility in Leuna, Germany. "We thank the German government for its continued investment in the growth of medical cannabis, made possible by decriminalization, which will improve access to medical cannabis for patients all across Germany," says Michael Simon, President, Aurora Europe. "Being one of the few companies to receive enhanced licenses is a testament to Aurora's established leadership in the region and unparalleled commitment to making available the highest quality cannabis. We now have the framework to extend our portfolio, invest in domestic research and leverage Aurora's global cultivation expertise locally." Aurora is committed to the growth, acceptance and broader access to medical cannabis globally. The company's leadership in Europe is a result of ongoing collaboration with government, regulators and industry. Since 2021, Aurora's medical cannabis production facility, located in Leuna, Saxony-Anhalt, has been cultivating approximately 1,000 kg (about 2204 lb) of medical cannabis flower annually as part of a tender agreement with BfArM. The company has demonstra

View on Read The Filing